This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases:cystic_fibrosis [02.18.2019] – [Evidence of infectious cause] sallieq | home:diseases:cystic_fibrosis [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 4: | Line 4: | ||
====== Cystic fibrosis ====== | ====== Cystic fibrosis ====== | ||
- | [[http:// | + | [[https:// |
- | [[http:// | + | [[https:// |
Line 13: | Line 13: | ||
===== Evidence of infectious cause ===== | ===== Evidence of infectious cause ===== | ||
+ | Pseudomonal infection in cystic fibrosis: the battle continues.(({{pmid> | ||
+ | < | ||
+ | Pseudomonas aeruginosa lung infection is the major cause of morbidity and mortality in patients with cystic fibrosis. Infection usually begins in childhood and is responsible for respiratory failure and death in most patients with cystic fibrosis. The organism triggers an exuberant chronic inflammatory reaction which damages the airways and leads to progressive loss of lung function. | ||
- | Expert Rev Anti Infect Ther. 2003 Dec; | + | This review provides an overview of pseudomonal |
- | Pseudomonal | + | |
- | Elkin S, Geddes D. | ||
- | Department of Cystic Fibrosis Royal Brompton Hospital London SW3 6NP, UK. sarah.elkin@st-marys.nhs.uk | ||
- | Pseudomonas aeruginosa lung infection is the major cause of morbidity and mortality in patients with cystic fibrosis. Infection usually begins in childhood and is responsible for respiratory failure and death in most patients with cystic fibrosis. The organism triggers an exuberant chronic inflammatory reaction which damages the airways and leads to progressive loss of lung function. Over the last decade significant advances have been made in the understanding of the pathophysiology of cystic fibrosis airways disease. These should assist the development of new and better therapies to treat this pathogen. This review provides an overview of pseudomonal infection in cystic fibrosis, including mechanisms by which the bacteria may colonize the cystic fibrosis airway, persistence of pseudomonal infection and the biofilm mode of growth. Available treatments and possible novel approaches to therapy will be discussed. | ||
- | (({{pubmed> | ||
- | < | + | Evolution of airway microbiology in the infant with cystic fibrosis: role of nonpseudomonal and pseudomonal pathogens.(({{pmid> |
+ | < | ||
- | ChIP-seq reveals the global regulator AlgR mediating cyclic di-GMP synthesis in Pseudomonas aeruginosa | + | |
+ | </ | ||
+ | |||
+ | ChIP-seq reveals the global regulator AlgR mediating cyclic di-GMP synthesis in Pseudomonas aeruginosa | ||
+ | < | ||
+ | |||
+ | A ΔalgR strain produced lesser biofilm than did the wild-type strain, which is consistent with a phenotype controlled by c-di-GMP. | ||
+ | </ | ||
+ | |||
+ | Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. | ||
+ | < | ||
+ | </ | ||
Line 31: | Line 41: | ||
{{tag> | {{tag> | ||
- | < | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 44: | Line 54: | ||
- | ===== References ===== | + | ===== References =====</ |